Bayer AG has failed to disclose to regulators potentially serious safety concerns about its antibleeding drug Trasylol. The FDA has disclosed that preliminary test results indicate that the drug may cause serious kidney damage, congestive heart failure and strokes and an increased risk of death.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.